Drug Profile
Research programme: hepatitis B vaccine and therapy - Dynavax
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in Asia (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B(Prevention) in USA (Parenteral, Injection)